Larson Financial Group LLC Acquires 689 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Larson Financial Group LLC increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 60.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,832 shares of the medical research company’s stock after purchasing an additional 689 shares during the period. Larson Financial Group LLC’s holdings in Bio-Rad Laboratories were worth $446,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in Bio-Rad Laboratories by 705.9% during the 4th quarter. Bank of America Corp DE now owns 427,292 shares of the medical research company’s stock worth $140,370,000 after purchasing an additional 374,269 shares in the last quarter. Ariel Investments LLC raised its stake in Bio-Rad Laboratories by 48.0% during the fourth quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company’s stock valued at $184,138,000 after buying an additional 181,829 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Bio-Rad Laboratories by 22,131.7% in the first quarter. GAMMA Investing LLC now owns 147,841 shares of the medical research company’s stock worth $36,008,000 after acquiring an additional 147,176 shares during the period. Norges Bank bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at about $41,644,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Bio-Rad Laboratories by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company’s stock valued at $245,106,000 after acquiring an additional 91,690 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BIO. Citigroup dropped their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. UBS Group lowered their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada cut their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 13th. Finally, Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an “equal weight” rating for the company in a report on Monday, June 9th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $324.25.

Bio-Rad Laboratories Trading Up 1.1%

Shares of BIO stock opened at $249.87 on Friday. The stock has a market cap of $6.80 billion, a price-to-earnings ratio of -3.28 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.43 and a current ratio of 5.99. The firm has a fifty day moving average of $238.15 and a 200-day moving average of $267.35. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The business had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same period in the previous year, the company earned $2.30 earnings per share. The firm’s revenue for the quarter was down 4.2% on a year-over-year basis. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.